Bioinformatics methods reveal CXCL2 as a key biomarker for diabetic nephropathy, suggesting potential treatment pathways.
Key Points
CXCL2 was identified as a diagnostic biomarker for diabetic nephropathy, indicating its elevated expression levels compared to the normal group.
The study conducted a comprehensive analysis using bioinformatics methods to identify demethylation-related genes in diabetic nephropathy and validate them as biomarkers.
Receiver operating characteristic curves confirmed the predictive accuracy of biomarkers, linking them with key molecular interactions and signaling pathways.
Subcellular localization and immune infiltration analyses suggested a complex relationship involving tumor suppressor genes and various immune cells in diabetic nephropathy.